Emergent Biosolutions (NYSE: EBS) — Company Overview, News & Financial Data
Emergent Biosolutions develops biopharmaceuticals for public health threats, focusing on infectious diseases and opioid overdoses.
Emergent Biosolutions
Emergent Biosolutions (NYSE:EBS) is a global biopharmaceutical company focused on developing, manufacturing, and commercializing medical countermeasures for public health threats. Through its multi-faceted approach, Emergent targets a wide range of pressing health concerns, from infectious diseases to opioid overdoses. With a portfolio that includes vaccines, therapeutics, and devices, Emergent aims to protect and enhance life by providing solutions that address some of the world's most pressing public health challenges. The company is also deeply involved in various projects aimed at combating emerging health threats, demonstrating its commitment to innovation and public service. By collaborating with governments, healthcare providers, and other key stakeholders, Emergent strives to fulfill its objective of making a significant impact on global health security.
Snapshot
Operations
Products and/or services of Emergent Biosolutions
- Narcan Nasal Spray for opioid overdose reversal is a life-saving medication that rapidly counters the effects of opioid drugs.
- BioThrax (Anthrax Vaccine Adsorbed) is the only FDA-approved vaccine for pre-exposure prophylaxis of anthrax disease.
- Raxibacumab, an antibody therapeutic, is used to treat inhalational anthrax, providing an alternative when traditional therapies are not suitable.
- Vivotif, an oral typhoid vaccine, offers protection against typhoid fever, a common and potentially severe bacterial infection.
- ACAM2000 is a vaccine for the prevention of smallpox, a critical component in biodefense against potential bioterrorism.
- BAT (Botulism Antitoxin Heptavalent) is a treatment for botulinum toxin types A through G, essential for addressing botulism poisoning.
Emergent Biosolutions executive team
- Joseph C. Papa Jr.CEO, President & Director
- Richard S. LindahlExecutive VP & CFO
- Coleen GlessnerExecutive Vice President of Quality, Ethics & Compliance
- Paul A. WilliamsSenior Vice President of Products Business
- Jessica PerlSenior VP, Corporate Secretary & General Counsel
- Assal HellmerVice President of Communications
- Michelle PepinSenior VP & Chief Human Resource Officer
- Stephanie DuatschekExecutive VP & Chief Growth Officer
- William HartzelSenior Vice President of Manufacturing & Bioservices
- Frank VargoVP & Treasurer
Dividend history
Dividends per share paid by Emergent Biosolutions, by financial year.
| Financial year | Interim | Final | Special | Total |
|---|---|---|---|---|
| FY2016 | — | — | — | $1.8550 |
Key financials
Reported results for Emergent Biosolutions, in USD.
- Market cap
- 370.2M
- Revenue (TTM)
- 770.2M
- P/E ratio
- —
- EPS (diluted, TTM)
- -3.5
- Dividend yield
- —
- Profit margin
- -23.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 742.9M | 110.2M | 52.6M | |
| 1B | -108.7M | -190.6M | |
| 1B | -726.4M | -760.5M | |
| 1.1B | -170M | -211.6M |